Global Rifaximin API Market Top Leading Players with Strategies and Forecast 2028

The global rifaximin API market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).  Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men.  Rifaximin is in a class of medications called antibiotics. Rifaximin treats traveler's diarrhea and irritable bowel syndrome by stopping the growth of the bacteria that cause diarrhea. Rifaximin treats hepatic encephalopathy by stopping the growth of bacteria that produce toxins and that may worsen liver disease.
 
Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. This non-systemic property of the drug is due to the addition of a pyridoimidazole ring, which renders it non-absorbable. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. The market is segmented based on the type. Based on the type the market is sub-segmented into 99% Purity, >99% Purity. Some major players in the market include Lupin Ltd., Salix Pharmaceuticals, Inc., LGM Pharma, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Rifaximin API Market at https://orionmarketreports.com/request-sample/?id=94432&submit=Request+Sample%0D%0A

Market Coverage
The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape- Lupin Ltd., Salix Pharmaceuticals, Inc., LGM Pharma, among others.

A full report is available at: https://orionmarketreports.com/global-rifaximin-api-market/94432/
 
Global Rifaximin API Market Report by Segment

By Type
99% Purity
>99% Purity
 
Global Rifaximin API Market Report by Region
North America
United States
Canada

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.